ADVANCE RESEARCH ON MONOCLONAL ANTIBODY FOR CANCER TREATMENHT
Abstract
Research and development of antitumor monoclonal antibody agents have shown substantial progress. Monoclonal antibodies (McAb) or their immunoconjugates can be used as clinically therapeutic agents for cancer treatment. As reported, McAb agents display specific binding to tumor-related targets, exhibit selective cytotoxicity to target cancer cells, and show highly therapeutic effects in animal experiments. Recently, some of the McAb agents have been applied in clinical therapy. Major trends in the study of McAb agents are searching for new relevant molecular targets, humanizing of the antibody, and downsizing of the immunoconjugate molecule. Due to high specificity of McAb to related molecular target, there is a great potential to develop highly effective antitumor agents. Thats why McAb agents may play an important role in cancer therapy.References
chwaber, J.: Cohen, E. P: "Human x mouse somatic cell hybrid clone secreting immunoglobulins of both parental types". Nature 244 :1973.
Science Citation Index
Cambrosio, A.; Keating, P: "Between fact and technique: the beginnings of hybridoma technology". Journal of the History of Biology 25 (2): 175–230: 1992.
Köhler, G.; Milstein, C. : "Continuous cultures of fused cells secreting antibody of predefined specificity". Nature 256 (5517): 495–497. Bibcode 1975Natur.256..495K: 1975.
Riechmann L, Clark M, Waldmann H, Winter G: "Reshaping human antibodies for therapy". Nature 332 (6162): 323–327. Bibcode 1988Natur.332..323R.:March 1988.
Stern M, Herrmann R : "Overview of monoclonal antibodies in cancer therapy: present and promise". Crit. Rev. Oncol. Hematol. 54 (1): 11–29: April 2005.
Carter P, Presta L, Gorman CM, et al : "Humanization of an anti-p185HER2 antibody for human cancer therapy". Proc. Natl. Acad. Sci. U.S.A. 89 (10): 4285–9: May 1992.
Presta LG, Lahr SJ, Shields RL, et al: "Humanization of an antibody directed against IgE". J. Immunol. 151 (5): 2623–32; September 1993.
Chothia C, Lesk AM, Tramontano A, et al: "Conformations of immunoglobulin hypervariable regions"; Nature 342 (6252): 877–83; 1989.
Waldmann, Thomas A: "Immunotherapy: past, present and future". Nature Medicine 9 (3): 269–277: 2003.
Hudson PJ, Souriau C : "Engineered antibodies". Nat. Med. 9 (1): 129–34: January 2003.
Janeway CA, Jr. et al: Immunobiology. (6th ed.). Garland Science. ISBN 0-443-07310-4: 2005.
Jefferis, Roy; Marie-Paule Lefranc : "Human immunoglobulin allotypes". MAbs 1 (4): 332–338: July/August 2009.
Chapman, Kathryn; Nick Pullen, Lee Coney, Maggie Dempster, Laura Andrews, Jeffrey Bajramovic, Paul Baldrick, Lorrene Buckley, Abby Jacobs, Geoff Hale, Colin Green, Ian Ragan and Vicky Robinson :"Preclinical development of monoclonal antibodies". MAbs 1 (5): 505–516: 2009.
http://edition.cnn.com/HEALTH/library/monoclonal-antibody/CA00082.html
Takimoto CH, Calvo E: "Principles of Oncologic Pharmacotherapy" in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management
Rang, H. P.; Pharmacology. Edinburgh: Churchill Livingstone. pp. 241, for the examples infliximab, basiliximab, abciximab, daclizumab, palivusamab, gemtuzumab, alemtuzumab and rituximab, and mechanism and mode: 2003.
British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. 63rd edition. 2012. British Medical Association and Royal Pharmaceutical Society of Great Britain.
National Institute for Health and Clinical Excellence (NICE). Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107); National Institute for Health and Clinical Excellence (NICE): August 2006.
National Institute for Health and Clinical Excellence (NICE).Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208); National Institute for Health and Clinical Excellence (NICE): November 2010.
National Institute for Health and Clinical Excellence (NICE). Guidance on the use of trastuzumab for the treatment of advanced breast cancer (CG81); National Institute for Health and Clinical Excellence (NICE): March 2002.
Scottish Medicines Consortium (SMC). Advice on 623/10 - Trastuzumab (Herceptin) Resubmission. February 2011. Scottish Medicines Consortium (SMC).
British National Formulary. 63rd edition. British Medical Association and Royal Pharmaceutical Society of Great Britain. 2012.
electronic Medicines Compendium (eMC): October 2012.
National Institute for Health and Clinical Excellence (NICE). Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242): 2012.
National Institute for Health and Clinical Excellence (NICE).Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck cancer (TA145): 2008.
National Institute for Health and Clinical Excellence (NICE). Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck cancer (TA172): 2009.
National Institute for Health and Clinical Excellence (NICE).Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176): 2009.
Scottish Medicines Consortium (SMC). 543/09 - Cetuximab (Erbitux): 2010.
Scottish Medicines Consortium (SMC). 279/06 - Cetuximab 2mg/ml intravenous infusion (Erbitux): 2006.
Bevacizumab for the treatment of non-small cell lung cancer (TA148). National Institute for Health and Clinical Excellence (NICE): June 2008.
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263). August 2012. National Institute for Health and Clinical Excellence (NICE).
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214). February 2011. National Institute for Health and Clinical Excellence (NICE).
459/08 - Bevacizumab (Avastin). Scottish Medicines Consortium (SMC): March 2008.
Balagula Y, et al. Dermatologic Toxicities of Targeted Anticancer Therapies. Supportive Oncology. July/August 2010. 8 (4): 149–161.
Colorectal cancer (metastatic) 2nd line –
cetuximab, bevacizumab and panitumumab (review) (TA242). National Institute for Health and Clinical Excellence (NICE): January 2012.
Colorectal cancer (metastatic) – panitumumab (terminated appraisal) (TA240). National Institute for Health and Clinical Excellence (NICE): December 2011.
electronic Medicines Compendium
(eMC) :October 2012.
769/12 – Panitumumab (Vectibix) Scottish Medicines Consortium (SMC): February 2012.